<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602511</url>
  </required_header>
  <id_info>
    <org_study_id>NMSG 17/07</org_study_id>
    <secondary_id>EudraCT no. 2007-001292-11</secondary_id>
    <nct_id>NCT00602511</nct_id>
  </id_info>
  <brief_title>Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma</brief_title>
  <official_title>Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Myeloma Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare thalidomide + dexamethasone with bortezomib +
      dexamethasone in patients with multiple myeloma refractory to melphalan therapy. The main
      goal is to find out which of these two 2:nd line regimens that offers the patients the best
      chance for a response with as long duration and as good quality of life as possible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open randomized multicentre study in which patients with multiple myeloma
      refractory to melphalan therapy are randomized between bortezomib and thalidomide therapy, in
      both arms with the addition of dexamethasone. In case of failure to the initially given
      treatment the patient will be crossed over to the alternative treatment.

      The number of patients needed is calculated to 300, based upon the hypothesis of a 50%
      difference in progression free survival, a significance level of 95% and a power of 80%. With
      12 patients being recruited each month during 25 months and a 4 months follow-up after the
      last included patient, the total study time will be 29 months.

      The dose regimens for bortezomib and thalidomide follow general clinical praxis as regards
      recommendations for optimal dosing in the Nordic countries.

      Evaluation of response and toxicity is performed every 3 weeks for at least 12 weeks,
      thereafter every 6 weeks. Evaluation of efficacy is done according to The International
      Myeloma Working Group Uniform Response Criteria. Evaluation of toxicity is done by CTCAE
      grading. Evaluation of quality of life is done by the EORTC QLQ30 questionnaires with the
      addition of the myeloma specific MY-24 module which are mailed to the patients at
      predetermined intervals during the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Not specified</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Not specified</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>Not specified</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to start of other treatment</measure>
    <time_frame>Not specified</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Not specified</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Not specified</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate after cross-over</measure>
    <time_frame>Not specified</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration after cross-over</measure>
    <time_frame>Not specified</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib - dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalidomide - dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles
Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day
Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment demanding multiple myeloma

          -  Refractoriness to melphalan

          -  Acceptance of rules for prevention of pregnancy

        Exclusion Criteria:

          -  Previous treatment with bortezomib, thalidomide, or lenalidomide

          -  Sensory neuropathy grade III or neuropathic pain grade II

          -  Severe concomitant disorder, e.g. other malignancy or severe heart disease

          -  Transformation to plasma cell leukemia or aggressive lymphoma

          -  Frequent visits for bortezomib injections not feasible

          -  Anticipated non-adherence to study protocol

          -  Pregnancy

          -  Anticipated non-adherence to rules for prevention of pregnancy

          -  Severe thrombocytopenia (Thrombocyte count less than 25000/microliter)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Hjorth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Lidköping Hospital, S-53185 Lidköping, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ålborg university Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Koebenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus University Hospital</name>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevål Sykehus</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonhjemmet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssykehus</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falun Hospital</name>
      <address>
        <city>Falun</city>
        <zip>79182</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <zip>25187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lidköping Hospital</name>
      <address>
        <city>Lidköping</city>
        <zip>53185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malmö University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mölndal hospital</name>
      <address>
        <city>Mölndal</city>
        <zip>43180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skövde Hospital</name>
      <address>
        <city>Skövde</city>
        <zip>54185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Göran Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>11281</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <zip>85186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <zip>45180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Västerås Hospital</name>
      <address>
        <city>Västerås</city>
        <zip>72189</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Växjö Hospital</name>
      <address>
        <city>Växjö</city>
        <zip>35185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örnsköldsvik Hospital</name>
      <address>
        <city>Örnsköldsvik</city>
        <zip>89189</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>February 8, 2011</last_update_submitted>
  <last_update_submitted_qc>February 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Martin Hjorth</name_title>
    <organization>Department of Medicine, Lidköping Hospital, S-53185 Lidköping, Sweden</organization>
  </responsible_party>
  <keyword>Melfalan refractory multiple myeloma</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>Relapsing</keyword>
  <keyword>Refractory</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Randomized clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

